Organon to Present New Research Findings at ISPOR 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy OGN?
Source: Newsfilter
- Research Presentation: Organon will showcase eight abstracts at ISPOR 2026, taking place from May 17-20 in Philadelphia, focusing on women's health, biosimilars, and neurology, highlighting its commitment to health economics and outcomes research aimed at improving patient health outcomes.
- Budget Impact Analysis: The analysis of NEXPLANON®'s cost-effectiveness and budget impact in Brazil will incorporate real-world utilization data and private payer perspectives, aiming to provide empirical support for healthcare decision-making and enhance market acceptance of the product.
- Biosimilar Adoption Study: Organon will present a budget impact analysis of POHERDY® for HER2-positive breast cancer treatment and a real-world budget impact analysis of biosimilar adoption in a mid-sized Brazilian health maintenance organization, aiming to drive market penetration of biosimilars.
- Patient Pathway Research: The exploration of real-world referral patterns and healthcare utilization among headache patients in the UK will contribute to a better understanding of patient pathways and healthcare resource use, providing data support for improving patient care in the neurology field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OGN
Wall Street analysts forecast OGN stock price to fall
5 Analyst Rating
0 Buy
1 Hold
4 Sell
Strong Sell
Current: 13.360
Low
5.00
Averages
8.50
High
12.00
Current: 13.360
Low
5.00
Averages
8.50
High
12.00
About OGN
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Organon to Present New Research Findings at ISPOR 2026
- Research Presentation: Organon will showcase eight abstracts at ISPOR 2026, taking place from May 17-20 in Philadelphia, focusing on women's health, biosimilars, and neurology, highlighting its commitment to health economics and outcomes research aimed at improving patient health outcomes.
- Budget Impact Analysis: The analysis of NEXPLANON®'s cost-effectiveness and budget impact in Brazil will incorporate real-world utilization data and private payer perspectives, aiming to provide empirical support for healthcare decision-making and enhance market acceptance of the product.
- Biosimilar Adoption Study: Organon will present a budget impact analysis of POHERDY® for HER2-positive breast cancer treatment and a real-world budget impact analysis of biosimilar adoption in a mid-sized Brazilian health maintenance organization, aiming to drive market penetration of biosimilars.
- Patient Pathway Research: The exploration of real-world referral patterns and healthcare utilization among headache patients in the UK will contribute to a better understanding of patient pathways and healthcare resource use, providing data support for improving patient care in the neurology field.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies such as XOMA Royalty Corporation, Organon & Co., and Veris Residential, Inc. for potential violations of federal securities laws and breaches of fiduciary duties to shareholders, with transaction prices at $39.00, $14.00, and $19.00 per share respectively, indicating potential threats to shareholder rights.
- Shareholder Rights Protection: The law firm encourages shareholders to contact them to discuss their rights and options, promising to provide legal services on a contingency fee basis, aiming to secure higher transaction prices and additional disclosures for affected investors, thereby enhancing legal protections for shareholders.
- Potential Impact: The investigation may lead to a reassessment of transaction terms, particularly those that could limit superior competing offers, and if successful, could yield greater financial benefits for shareholders, reflecting a commitment to corporate governance and transparency.
- Legal Service Commitment: Halper Sadeh LLC states it will represent investors globally in seeking legal remedies, having previously recovered millions for victims of securities fraud, showcasing its expertise and influence in addressing corporate misconduct.
See More
Investigations into Multiple Company Acquisitions
- Veris Acquisition Investigation: Veris Residential, Inc. is set to be acquired by Affinius Capital for $19.00 per share, representing an enterprise value of $3.4 billion, with investigations focusing on whether the board failed to conduct a fair process, potentially impacting shareholder rights.
- XOMA Transaction Scrutiny: XOMA Royalty Corporation will be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million, with investigations questioning whether the board ensured fair value for shareholders, especially as the offer is below the 52-week high of $42.38.
- Organon Acquisition Concerns: Organon & Co. is to be acquired by Sun Pharmaceutical for $14.00 per share, with an enterprise valuation of $11.75 billion, and investigations are looking into whether the board failed to conduct a fair process, which could harm shareholder interests.
- RE/MAX Transaction Investigation: RE/MAX Holdings, Inc. will be acquired by The Real Brokerage, allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash per share, with investigations questioning whether the board ensured the fairness of the transaction, potentially affecting shareholder rights.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Merger Investigation: Halper Sadeh LLC is investigating the merger between Helix Energy Solutions Group, Inc. and Hornbeck Offshore Services, Inc., with Helix shareholders expected to own approximately 45% of the combined entity, potentially impacting shareholder rights and future earnings.
- Acquisition Review: Organon & Co. is being sold to Sun Pharmaceutical Industries Limited for $14.00 per share, and Halper Sadeh LLC may seek increased compensation and additional disclosures to ensure shareholder rights are protected.
- Equity Transaction: XOMA Royalty Corporation is being sold to Ligand Pharmaceuticals Incorporated for $39.00 per share, with Halper Sadeh LLC representing shareholders to investigate the compliance of this transaction and ensure fair terms for shareholders.
- RE/MAX Deal: RE/MAX Holdings, Inc. is in a transaction with The Real Brokerage Inc., allowing shareholders to choose either 5.152 shares or $13.80 in cash per share, with Halper Sadeh LLC providing legal support to safeguard shareholder interests.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Merger Investigation: Halper Sadeh LLC is investigating the merger between McCormick & Company and Unilever's Foods business, where McCormick shareholders will own 35% of the combined company upon closing, potentially impacting shareholder rights and market competition.
- Shareholder Rights Protection: Leggett & Platt is selling to Somnigroup International Inc. for 0.1455 shares of Somnigroup common stock per share of Leggett & Platt, resulting in shareholders owning approximately 9% of the combined company, prompting Halper Sadeh LLC to remind shareholders of their legal rights.
- Acquisition Price Dispute: Organon & Co. is being sold to Sun Pharmaceutical Industries for $14.00 per share, with Halper Sadeh LLC potentially seeking to increase the acquisition price to ensure shareholders receive fair compensation.
- Internal Transaction Review: Kennedy-Wilson Holdings is being sold for $10.90 per share in cash to a consortium led by executives, with Halper Sadeh LLC possibly requesting additional information and disclosures to protect shareholder interests.
See More
Investigation Alerts for Multiple Company Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to uphold fiduciary duties to ensure a fair process for shareholders.
- RE/MAX Merger Investigation: RE/MAX Holdings, Inc. is being acquired by The Real Brokerage Inc., allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash, with investigations looking into whether the Board adequately handled the transaction to protect shareholder interests.
- Soleno Acquisition Case: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total equity value of approximately $2.9 billion, while the investigation questions whether the Board ensured the deal was fair to shareholders, given that the price is below its 52-week high of $90.32.
See More
Organon to Present New Research Findings at ISPOR 2026
- Research Presentation: Organon will showcase eight abstracts at ISPOR 2026, taking place from May 17-20 in Philadelphia, focusing on women's health, biosimilars, and neurology, highlighting its commitment to health economics and outcomes research aimed at improving patient health outcomes.
- Budget Impact Analysis: The analysis of NEXPLANON®'s cost-effectiveness and budget impact in Brazil will incorporate real-world utilization data and private payer perspectives, aiming to provide empirical support for healthcare decision-making and enhance market acceptance of the product.
- Biosimilar Adoption Study: Organon will present a budget impact analysis of POHERDY® for HER2-positive breast cancer treatment and a real-world budget impact analysis of biosimilar adoption in a mid-sized Brazilian health maintenance organization, aiming to drive market penetration of biosimilars.
- Patient Pathway Research: The exploration of real-world referral patterns and healthcare utilization among headache patients in the UK will contribute to a better understanding of patient pathways and healthcare resource use, providing data support for improving patient care in the neurology field.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies such as XOMA Royalty Corporation, Organon & Co., and Veris Residential, Inc. for potential violations of federal securities laws and breaches of fiduciary duties to shareholders, with transaction prices at $39.00, $14.00, and $19.00 per share respectively, indicating potential threats to shareholder rights.
- Shareholder Rights Protection: The law firm encourages shareholders to contact them to discuss their rights and options, promising to provide legal services on a contingency fee basis, aiming to secure higher transaction prices and additional disclosures for affected investors, thereby enhancing legal protections for shareholders.
- Potential Impact: The investigation may lead to a reassessment of transaction terms, particularly those that could limit superior competing offers, and if successful, could yield greater financial benefits for shareholders, reflecting a commitment to corporate governance and transparency.
- Legal Service Commitment: Halper Sadeh LLC states it will represent investors globally in seeking legal remedies, having previously recovered millions for victims of securities fraud, showcasing its expertise and influence in addressing corporate misconduct.
See More
Investigations into Multiple Company Acquisitions
- Veris Acquisition Investigation: Veris Residential, Inc. is set to be acquired by Affinius Capital for $19.00 per share, representing an enterprise value of $3.4 billion, with investigations focusing on whether the board failed to conduct a fair process, potentially impacting shareholder rights.
- XOMA Transaction Scrutiny: XOMA Royalty Corporation will be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million, with investigations questioning whether the board ensured fair value for shareholders, especially as the offer is below the 52-week high of $42.38.
- Organon Acquisition Concerns: Organon & Co. is to be acquired by Sun Pharmaceutical for $14.00 per share, with an enterprise valuation of $11.75 billion, and investigations are looking into whether the board failed to conduct a fair process, which could harm shareholder interests.
- RE/MAX Transaction Investigation: RE/MAX Holdings, Inc. will be acquired by The Real Brokerage, allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash per share, with investigations questioning whether the board ensured the fairness of the transaction, potentially affecting shareholder rights.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Merger Investigation: Halper Sadeh LLC is investigating the merger between Helix Energy Solutions Group, Inc. and Hornbeck Offshore Services, Inc., with Helix shareholders expected to own approximately 45% of the combined entity, potentially impacting shareholder rights and future earnings.
- Acquisition Review: Organon & Co. is being sold to Sun Pharmaceutical Industries Limited for $14.00 per share, and Halper Sadeh LLC may seek increased compensation and additional disclosures to ensure shareholder rights are protected.
- Equity Transaction: XOMA Royalty Corporation is being sold to Ligand Pharmaceuticals Incorporated for $39.00 per share, with Halper Sadeh LLC representing shareholders to investigate the compliance of this transaction and ensure fair terms for shareholders.
- RE/MAX Deal: RE/MAX Holdings, Inc. is in a transaction with The Real Brokerage Inc., allowing shareholders to choose either 5.152 shares or $13.80 in cash per share, with Halper Sadeh LLC providing legal support to safeguard shareholder interests.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Merger Investigation: Halper Sadeh LLC is investigating the merger between McCormick & Company and Unilever's Foods business, where McCormick shareholders will own 35% of the combined company upon closing, potentially impacting shareholder rights and market competition.
- Shareholder Rights Protection: Leggett & Platt is selling to Somnigroup International Inc. for 0.1455 shares of Somnigroup common stock per share of Leggett & Platt, resulting in shareholders owning approximately 9% of the combined company, prompting Halper Sadeh LLC to remind shareholders of their legal rights.
- Acquisition Price Dispute: Organon & Co. is being sold to Sun Pharmaceutical Industries for $14.00 per share, with Halper Sadeh LLC potentially seeking to increase the acquisition price to ensure shareholders receive fair compensation.
- Internal Transaction Review: Kennedy-Wilson Holdings is being sold for $10.90 per share in cash to a consortium led by executives, with Halper Sadeh LLC possibly requesting additional information and disclosures to protect shareholder interests.
See More
Investigation Alerts for Multiple Company Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to uphold fiduciary duties to ensure a fair process for shareholders.
- RE/MAX Merger Investigation: RE/MAX Holdings, Inc. is being acquired by The Real Brokerage Inc., allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash, with investigations looking into whether the Board adequately handled the transaction to protect shareholder interests.
- Soleno Acquisition Case: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total equity value of approximately $2.9 billion, while the investigation questions whether the Board ensured the deal was fair to shareholders, given that the price is below its 52-week high of $90.32.
See More
